V. Azapirones
V. Azapirones
V. Azapirones
Generic Name:
Classification: AZAPIRONES
PO (Adults): 7.5 mg twice daily;qby 5 mg/day q 2– 4 days as needed (not to exceed 60 mg/day). Usual
dose is 20– 30 mg/day (in 2 divided doses).
Binds to serotonin and dopamine receptors in the brain. Increases norepinephrine metabolism in the
brain. Therapeutic Effects: Relief of anxiety
Absorption: Rapidly absorbed. Distribution: Unknown
Metabolism and Excretion: Extensively metabolized by the liver (CYP3A4 enzyme system); 20– 40%
excreted in feces.
Drug-Drug: Use with MAO inhibitors may result in hypertension and is not recommended
Drug-Natural Products: Concomitant use of kava-kava,valerian, orchamomile can↑CNS depression.
Drug-Food: Grapefruit juice ↑ serum levels and effect; ingestion of large amounts of grapefruit juice is
not recommended.
Indications:
Management of anxiety.
Contraindications:
Contraindicated in: Hypersensitivity; Severe hepatic or renal impairment; Concurrent use of MAO
inhibitors; Ingestion of large amounts of grapefruit juice. Use Cautiously in: Patients receiving other
antianxiety agents (other agents should be slowly withdrawn to prevent withdrawal or rebound
phenomenon); Patients receiving other psychotropics;
CNS: dizziness, drowsiness, excitement, fatigue, headache, insomnia, nervousness EENT: blurred vision,
sore throat GI: nausea, abdominal pain, constipation, diarrhea, dry mouth, vomiting
Assessment
● Assess degree and manifestations of anxiety before and periodically during therapy. ● Buspirone does
not appear to cause physical or psychological dependence or tolerance. However, patients with a history
of substance use disorder should be assessed for tolerance or impaired control. Restrict amount of drug
available to these patients.
Anxiety (Indications)
Risk for injury (Side Effects)
Implementation
● Do not confuse buspirone with bupropion. ● Patients changing from other antianxiety agents should
receive gradually decreasing doses. Buspirone will not prevent withdrawal symptoms. ● PO: May be
administered with food to minimize gastric irritation. Food slows but does not alter extent of
absorption.
Patient/Family Teaching
Instruct patient to notify health care professional if any chronic abnormal movements occur (dystonia,
motor restlessness, involuntary movements of facial or cervical muscles) or if pregnancy is suspected.
Evaluation/Desired Outcomes
● Increase in sense of well-being. ● Decrease in subjective feelings of anxiety. Some improvement may
be seen in 7– 10 days. Optimal results take 3– 4 wk of therapy. Buspirone is usually used for short-term
therapy (3– 4 wk). If prescribed for long-term therapy, efficacy should be periodically assessed.